|
1
|
Ritossa F: Discovery of the heat shock
response. Cell Stress Chaperones. 1:97–98. 1996. View Article : Google Scholar
|
|
2
|
Westerheide SD and Morimoto RI: Heat shock
response modulators as therapeutic tools for the diseases of
protein conformation. J Biol Chem. 280:33097–33100. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wiech H, Buchner J, Zimmerman R and Jakob
U: Hsp90 chaperones protein folding in vitro. Nature. 358:169–170.
1992. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schneider C, Sepp-Lorenzino I, Nimmersgern
E, Ouerfelli O, Danishefsky S, Rosen N and Harti FU: Pharmacologic
shifting of a balance between protein refolding and degradation
mediated by Hsp90. Proc Natl Acad Sci USA. 93:14536–14541. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao R, Davey M, Hsu Y, Kaplanek P, Tong
A, Parsons AB, Krogan N, Cagney G, Mal D, Greenblatt J, Boone C,
Emili A and Houry WA: Navigating the chaperone network: an
integrative map of physical and genetic interactions mediated by
the hsp90 chaperone. Cell. 120:715–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Neckers L: Hsp90 inhibitors as novel
cancer chemotherapeutic agents. Trends Mol Med. 8(suppl 4):
S55–S61. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Russell JS, Burgan WE, Oswald KA,
Camphausen K and Tofilon PJ: Enhanced cell killing induced by the
combination of radiation and the heat shock protein 90 inhibitor
17-allylamino-17-demethoxygeldanamycin: a multitarget approach to
radiosensitization. Clin Cancer Res. 37:3749–3755. 2003.PubMed/NCBI
|
|
8
|
Machida H, Matsumoto Y, Shirai M and
Kubota N: Geldanamycin, an inhibitor of Hsp90, sensitizes human
tumor cells to radiation. Int J Radiat Biol. 79:973–980. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Machida H, Nakajima S, Shikano N, Nishio
J, Okada S, Asayama M, Shirai M and Kubota N: Heat shock protein 90
inhibitor 17-allylamino-17-demethoxygeldamamycin potentiates the
radiation response of tumor cells grown as monolayer cultures and
spheroids by inducing apoptosis. Cancer Sci. 96:911–917. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matsumoto Y, Machida H and Kubota N:
Preferential sensitization of tumor cells to radiation by heat
shock protein 90 inhibitor geldanamycin. J Radiat Res. 46:215–221.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Noguchi M, Yu D, Hirayama R, Ninomiya Y,
Sekine E, Kubota N, Ando K and Okayasu R: Inhibition of homologous
recombination repair in irradiated tumor cells pretreated with
Hsp90 inhibitor 17-allylamino-17-demethoxygeldamamycin. Biochem
Biophys Res Commun. 351:658–663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Solit DB, Ivy SP, Kopil C, Sikorski R,
Morris MJ, SF, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G,
Larson S, Schwartz L, Egorin MJ, Rosen N and Scher HI: Phase I
trial of 17-allylamino-17-demethoxygeldanamycin in patients with
advanced cancer. Clin Cancer Res. 13:1775–1782. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Taldone T, Gozman Maharaj R and Chiosis G:
Targeting Hsp90: small-molecule inhibitors and their clinical
development. Curr Opin Pharmacol. 8:370–374. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiosis G, Kang Y and Sun W: Discovery and
development of purine-scaffold Hsp90 inhibitors. Expert Opin Drug
Discov. 3:99–114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Caldas-Lopes E, Cerchietti L, Ahn JH,
Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A,
Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski
L, Melnick A and Chiosis G: Hsp90 inhibitor PU-H71, a multimodal
inhibitor of malignancy, induces complete responses in
triple-negative breast cancer models. Proc Natl Acad Sci USA.
106:8368–8373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Briones J: Targeted therapy of
BCL6-dependent diffuse large B-cell lymphoma by heat-shock protein
90 inhibition. Expert Rev Hematol. 3:157–159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Breinig M, Caldas-Lopes E, Goeppert B,
Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G and
Kern MA: Targeting heat shock protein 90 with non-quinone
inhibitors: a novel chemotherapeutic approach in human
hepatocellular carcinoma. Hepatology. 50:102–112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li X and Heyer WD: Homologous
recombination in DNA repair and DNA damage tolerance. Cell Res.
18:99–113. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kuribayashi T, Ohara M, Sora S and Kubota
N: Scriptaid, a novel histone deacetylase inhibitor, enhances the
response of human tumor cells to radiation. Int J Mol Med.
25:25–29. 2010.PubMed/NCBI
|
|
20
|
Bee L, Fabris S, Cherubini R, Mognato M
and Celotti L: The efficiency of homologous recombination and
non-homologous end joining systems in repairing double-strand
breaks during cell cycle progression. PloS One. 8:e690612013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bull EE, Dote H, Brady KJ, Burgan WE,
Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K and
Tofilon PJ: Enhanced tumor cell radiosensitivity and abrogation of
G2 and S phase arrest by the Hsp90 inhibitor
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer
Res. 10:8077–8084. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bisht KS, Bradbury CM, Mattson D, Kaushal
A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel
MW, Mitchell JB, Neckers LM and Gius D: Geldanamycin and
17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and
in vivo radiation response of cervical tumor cells via the heat
shock protein 90-mediated intracellular signaling and cytotoxicity.
Cancer Res. 63:8984–8995. 2003.
|
|
23
|
Koll TT, Feis SS, Wright MH, Teniola MM,
Richardson MM, Robles AI, Bradsher J, Capala J and Varticovski L:
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer
cells by interfering with base excision and ATM-mediated DNA
repair. Mol Cancer Ther. 7:1985–1992. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stingl L, Stühmer T, Chatterjee M, Jensen
MR, Flentje M and Djuzenova CS: Novel HSP90 inhibitors, NVP-AUY922
and NVP-BEP800, radiosensitise tumour cells through cell-cycle
impairment, increased DNA damage and repair protraction. Br J
Cancer. 102:1578–1591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kubota N and Matsumoto Y: Hsp90 inhibitors
are promising radiosensitizers for radiotherapy. Thermal Med.
28:53–62. 2012. View Article : Google Scholar
|
|
26
|
Sharp S and Workman P: Inhibitors of the
HSP90 molecular chaperone: current status. Adv Cancer Res.
95:323–348. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chiosis G, Timaul MN, Lucas B, Munster PN,
Zheng FF, Sepp-Lorenzino L and Rosen N: A small molecule designed
to bind to the adenine nucleotide pocket of Hsp90 causes Her2
degradation and the growth arrest and differentiation of breast
cancer cells. Chem Biol. 8:289–299. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiosis G: Discovery and development of
purine-scaffold Hsp90 inhibitors. Curr Top Med Chem. 6:1183–1191.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chiosis G, Rodina A and Moulick K:
Emerging Hsp90 inhibitors: from discovery to clinic. Anticancer
Agents Med Chem. 6:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zaidi S, McLaughlin M, Bhide SA, Eccles
SA, Workman P, Nutting CM, Huddart RA and Harrington KJ: The HSP90
inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous
recombination resulting in mitotic entry with unresolved DNA
damage. PLos One. 7:e354362012. View Article : Google Scholar : PubMed/NCBI
|
